AllianceBernstein
ZNTL icon

AllianceBernstein’s Zentalis Pharmaceuticals ZNTL Stock Holding History

AllianceBernstein’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40K Buy
+17,100
New +$68.3K ﹤0.01% 3306
2025
Q2 		– Sell
-109,538
Closed -$174K – 3350
2025
Q1 		$174K Hold
109,538
– – ﹤0.01% 2962
2024
Q4 		$332K Hold
109,538
– – ﹤0.01% 2817
2024
Q3 		$403K Sell
109,538
-1,200
-1% -$4.36K ﹤0.01% 2772
2024
Q2 		$453K Buy
110,738
+53,020
+92% +$592K ﹤0.01% 2722
2024
Q1 		$910K Hold
57,718
– – ﹤0.01% 2318
2023
Q4 		$874K Hold
57,718
– – ﹤0.01% 2341
2023
Q3 		$1.16M Sell
57,718
-1,263,717
-96% -$32.1M ﹤0.01% 2159
2023
Q2 		$37.3M Buy
1,321,435
+31,139
+2% +$747K 0.02% 662
2023
Q1 		$22.2M Sell
1,290,296
-75,202
-6% -$1.52M 0.01% 801
2022
Q4 		$27.5M Buy
1,365,498
+33,614
+3% +$723K 0.01% 747
2022
Q3 		$28.8M Sell
1,331,884
-22,579
-2% -$617K 0.01% 725
2022
Q2 		$38.1M Buy
1,354,463
+357,704
+36% +$9.48M 0.02% 653
2022
Q1 		$46M Buy
996,759
+69,822
+8% +$3.77M 0.02% 622
2021
Q4 		$77.9M Sell
926,937
-59,016
-6% -$4.57M 0.03% 504
2021
Q3 		$65.7M Buy
985,953
+45,125
+5% +$2.6M 0.03% 539
2021
Q2 		$50.1M Sell
940,828
-164,454
-15% -$8.81M 0.02% 622
2021
Q1 		$48M Buy
1,105,282
+270,834
+32% +$11.7M 0.02% 622
2020
Q4 		$43.3M Buy
834,448
+63,678
+8% +$2.87M 0.02% 624
2020
Q3 		$25.2M Buy
770,770
+272,498
+55% +$9.54M 0.01% 737
2020
Q2 		$23.9M Buy
+498,272
New +$19.1M 0.01% 712

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

AllianceBernstein's ZNTL Position: Q2 2026 in Review

AllianceBernstein opened a new position in Zentalis Pharmaceuticals (ZNTL) in Q2 2026: 17,100 shares worth $40K. The stake represents ﹤0.01% of the portfolio and ranks #3306 among its holdings. This is a return to the name: AllianceBernstein previously reported a position in ZNTL as recently as Q1 2025.

AllianceBernstein first reported a position in ZNTL in Q2 2020 and has held it in 21 quarters since. The position peaked at $77.9M in Q4 2021. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • AllianceBernstein held 17,100 shares of Zentalis Pharmaceuticals worth $40K as of Q2 2026.
  • Zentalis Pharmaceuticals was a new AllianceBernstein position in Q2 2026.
  • Zentalis Pharmaceuticals made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #3306 holding.
  • AllianceBernstein first reported a position in Zentalis Pharmaceuticals in Q2 2020 and has held it in 21 quarters since.
  • AllianceBernstein's Zentalis Pharmaceuticals position peaked at $77.9M in Q4 2021.
  • 114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.